ArticleActa pharmaceutica Sinica. B2023
An mRNA vaccine elicits STING-dependent antitumor immune responses.
Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- A dual-antigen mRNA-lipid polyplex vaccine elicits durable multistage immunity and sterile protection against malaria in mice.Acta pharmacologica Sinica · 2026Article
- Spatiotemporal control of STING activation and saRNA delivery decouples humoral and cellular immunity.bioRxiv : the preprint server for biology · 2026Article
- Targeted nanoparticles with triggered lysosomal escape enable anti-angiogenic immunotherapy for peritoneal metastatic colorectal cancer.Acta pharmaceutica Sinica. B · 2026Article
- Nanotechnology-mediated precision delivery of mRNA.Nature materials · 2026Review
- Review
- Ionizable guanidine-based lipid nanoparticle for targeted mRNA delivery and cancer immunotherapy.Science advances · 2025Article
- Advances and Strategies in Enhancing mRNA Cancer Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Biomaterials nanoplatform-based tumor vaccines for immunotherapy.Bioactive materials · 2025Review
- mRNA-LNP Vaccines Targeting SmpA-PLD and OmpK-Omp22 Induce Protective Immunity AgainstVaccines · 2025Article
- Tumor microenvironment-activated Zn//MnOScience advances · 2025Article
- Intravenous delivery of STING agonists using acid-sensitive polycationic polymer-modified lipid nanoparticles for enhanced tumor immunotherapy.Acta pharmaceutica Sinica. B · 2025Article
- mRNA vaccines in the context of cancer treatment: from concept to application.Journal of translational medicine · 2025Review
- Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions.Oncology research · 2025Review
- mRNA vaccines as cancer therapies.Chinese medical journal · 2024Review
- Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity.Science advances · 2024Article
- mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends.Biomarker research · 2024Review
- Mitophagy and cGAS-STING crosstalk in neuroinflammation.Acta pharmaceutica Sinica. B · 2024Review
- Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development.International journal of molecular sciences · 2024Review
- A stumbling block in pancreatic cancer treatment: drug resistance signaling networks.Frontiers in cell and developmental biology · 2024Review
- mRNA-based platform for preventing and treatingFrontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid-formulated RNA vaccines have been widely used for disease prevention and treatment, yet their mechanism of action and individual components contributing to such actions remain to be delineated. Here, we show that a therapeutic cancer vaccine composed of a protamine/mRNA core and a lipid shell is highly potent in promoting cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.